Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study

被引:276
|
作者
Khunti, Kamlesh [1 ,2 ]
Davies, Melanie [1 ,2 ]
Majeed, Azeem [3 ]
Thorsted, Brian Larsen [4 ]
Wolden, Michael Lyng [4 ]
Paul, Sanjoy K. [5 ]
机构
[1] Univ Leicester, Leicester Diabet Ctr, Leicester, Leics, England
[2] Univ Leicester, Leicester Clin Trials Unit, Leicester, Leics, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Publ Hlth & Primary Care, London, England
[4] Novo Nordisk AS, Bagsvaerd, Denmark
[5] QIMR Berghofer Med Res Inst, Clin Trials & Biostat Unit, Brisbane, Qld, Australia
关键词
GLYCEMIC CONTROL; GLUCOSE CONTROL; COMPLICATIONS; VETERANS; EVENTS;
D O I
10.2337/dc14-0920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVEHypoglycemia has been associated with an increased risk of cardiovascular (CV) events and all-cause mortality. This study assessed whether, in a nationally representative population, there is an association between hypoglycemia, the risk of CV events, and all-cause mortality among insulin-treated people with type 1 diabetes or type 2 diabetes.RESEARCH DESIGN AND METHODSThis retrospective cohort study used data from the Clinical Practice Research Datalink database and included all insulin-treated patients (30 years of age) with a diagnosis of diabetes.RESULTSIn patients who experienced hypoglycemia, hazard ratios (HRs) for CV events in people with type 1 diabetes were 1.51 (95% CI 0.83, 2.75; P = ns) and 1.61 (1.17, 2.22), respectively, for those with and without a history of CV disease (CVD) before the index date. In people with type 2 diabetes, the HRs for patients with and without a history of CVD were 1.60 (1.21, 2.12) and 1.49 (1.23, 1.82), respectively. For all-cause mortality, HRs in people with type 1 diabetes were 1.98 (1.25, 3.17), and 2.03 (1.66, 2.47), respectively, for those with and without a history of CVD. Among people with type 2 diabetes, HRs were 1.74 (1.39, 2.18) and 2.48 (2.21, 2.79), respectively, for those with and without a history of CVD. The median time (interquartile range) from first hypoglycemia event to first CV event was 1.5 years (0.5, 3.5 years) and 1.5 years (0.5, 3.0 years), respectively, for people with type 1 and type 2 diabetes.CONCLUSIONSHypoglycemia is associated with an increased risk of CV events and all-cause mortality in insulin-treated patients with diabetes. The relationship between hypoglycemia and CV outcomes and mortality exists over a long period.
引用
收藏
页码:316 / 322
页数:7
相关论文
共 50 条
  • [31] Longitudinal trends in HbA1c and associations with comorbidity and all-cause mortality in Asian patients with type 2 diabetes: A cohort study
    Luo, Miyang
    Lim, Wei Yen
    Tan, Chuen Seng
    Ning, Yilin
    Chia, Kee Seng
    van Dam, Rob M.
    Tang, Wern Ee
    Tan, Ngiap Chuan
    Chen, Richard
    Tai, E. Shyong
    Venkataraman, Kavita
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 133 : 69 - 77
  • [32] Different levels of hypoglycemia in patients with type 2 diabetes, their achieved mean HbA1c vs. all-cause and cardiovascular mortality
    Ooi, Seng-Wei
    Yeh, Shu-Tin
    Chang, Ya-Hui
    Li, Chung-Yi
    Chen, Hua-Fen
    PLOS ONE, 2023, 18 (07):
  • [33] Synergistic effect of chronic kidney disease, neuropathy, and retinopathy on all-cause mortality in type 1 and type 2 diabetes: a 21-year longitudinal study
    Sacchetta, Luca
    Chiriaco, Martina
    Nesti, Lorenzo
    Leonetti, Simone
    Forotti, Giovanna
    Natali, Andrea
    Solini, Anna
    Trico, Domenico
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [34] Severity of posttraumatic stress disorder, type 2 diabetes outcomes and all-cause mortality: A retrospective cohort study
    Salas, Joanne
    Wang, Wenjin
    Schnurr, Paula P.
    Cohen, Beth E.
    Freedland, Kenneth E.
    Jaffe, Allan S.
    Lustman, Patrick J.
    Friedman, Matthew
    Scherrer, Jeffrey F.
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2023, 175
  • [35] Validation in type 2 diabetes of a metabolomic signature of all-cause mortality
    Copetti, Massimiliano
    Baroni, Marco Giorgio
    Buzzetti, Raffaella
    Cavallo, Maria Gisella
    Cossu, Efiso
    D'Angelo, Paola
    De Cosmo, Salvatore
    Leonetti, Frida
    Morano, Susanna
    Morviducci, Lelio
    Napoli, Nicola
    Prudente, Sabrina
    Pugliese, Giuseppe
    Savino, Antonio Fernando
    Trischitta, Vincenzo
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2024, 40 (02)
  • [36] Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting - The Fremantle Diabetes Study
    Ong, Greg
    Davis, Timothy M. E.
    Davis, Wendy A.
    DIABETES CARE, 2010, 33 (02) : 317 - 321
  • [37] Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause Mortality
    Nichols, Gregory A.
    Joshua-Gotlib, Sandra
    Parasuraman, Shreekant
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (02) : 121 - 127
  • [38] Effect modification of glycemic control on association of lung function with all-cause and cardiovascular mortality in persons with type 2 diabetes - A retrospective cohort study
    Lin, Cheng-Chieh
    Li, Chia-Ing
    Yang, Chuan-Wei
    Liu, Chiu-Shong
    Lin, Chih-Hsueh
    Yang, Shing-Yu
    Li, Tsai-Chung
    RESPIRATORY MEDICINE, 2024, 234
  • [39] Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries
    Haluzik, Martin
    Kretowski, Adam
    Strojek, Krzysztof
    Czupryniak, Leszek
    Janez, Andrej
    Kempler, Peter
    Andel, Michal
    Tankova, Tsvetalina
    Boyanov, Mihail
    Duvnjak, Lea Smircic
    Madacsy, Laszlo
    Tarnowska, Iwona
    Zychma, Marcin
    Lalic, Nebojsa
    DIABETES THERAPY, 2018, 9 (02) : 727 - 741
  • [40] Circulating Metabolites Associate With and Improve the Prediction of All-Cause Mortality in Type 2 Diabetes
    Scarale, Maria Giovanna
    Mastroianno, Mario
    Prehn, Cornelia
    Copetti, Massimiliano
    Salvemini, Lucia
    Adamski, Jerzy
    De Cosmo, Salvatore
    Trischitta, Vincenzo
    Menzaghi, Claudia
    DIABETES, 2022, 71 (06) : 1363 - 1370